Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Classification of Skeletal Muscle Relaxants01:28

Classification of Skeletal Muscle Relaxants

3.6K
Skeletal muscle relaxants are a group of drugs that can reduce muscle stiffness and induce temporary paralysis to relieve pain. These agents can act centrally to reduce muscle tone or spasms in painful conditions such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), or spinal injuries; they are called antispasmodics or spasmolytics.
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
3.6K
Spasmolytic Agents: Chemical Classification01:29

Spasmolytic Agents: Chemical Classification

1.5K
Spasmolytic agents are drugs used to alleviate muscle spasms and spasticity. They can be categorized into different chemical groups based on their mechanisms of action. Centrally acting spasmolytics primarily affect the spinal cord, while others directly target skeletal muscle cells.
A major class of centrally acting spasmolytics is the α2-agonist, such as tizanidine. These drugs bind to α2-adrenoceptors, inhibiting the release of the excitatory neurotransmitter glutamate. They also...
1.5K
Peripherally and Centrally Acting Muscle Relaxants: A Comparison01:09

Peripherally and Centrally Acting Muscle Relaxants: A Comparison

5.7K
Skeletal muscle relaxants can target the central nervous system [CNS] to reduce muscle tension or act directly at the neuromuscular junction to induce temporary paralysis. These two classes of muscle relaxants are called centrally acting muscle relaxants and peripherally acting muscle relaxants. They differ in their action, mechanism, administration route, and clinical uses.
Centrally acting muscle relaxants can be further divided into spasmolytic and antispasmodic drugs. Spasmolytic...
5.7K
Centrally Acting Muscle Relaxants: Therapeutic Uses01:24

Centrally Acting Muscle Relaxants: Therapeutic Uses

1.7K
Centrally acting muscle relaxants reduce muscle tone and tension by interfering with the postsynaptic reflexes in the central nervous system.
Centrally acting drugs are classified into spasmolytic and antispasmodic drugs. Spasmolytic drugs such as baclofen, diazepam, and tizanidine inhibit spinal motor neurons and decrease muscle tone. Spasmolytic drugs are administered for severe and chronic spasms due to multiple sclerosis, cerebral palsy, stroke, and spinal cord and muscle injuries. However,...
1.7K
CNS Stimulants: Cocaine, Amphetamines and Cannabinoids01:24

CNS Stimulants: Cocaine, Amphetamines and Cannabinoids

1.5K
CNS stimulants, such as cocaine, amphetamines, and cannabinoids, have varying structures and mechanisms of action that lead to different therapeutic effects and side effects. Cocaine, with its molecular formula C17H21NO4, is a tropane alkaloid and a tertiary amino compound. It has two chemical forms: the hydrochloride salt and the "freebase." The former is in powder form, while the latter involves removing the hydrochloride salt to create a form that can be smoked. Cocaine exerts its...
1.5K
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids01:21

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

1.1K
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
1.1K

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Interrelationships between social exclusion, mental health and wellbeing in adolescents: insights from a national <i>Youth Survey</i>.

Epidemiology and psychiatric sciences·2025
Same author

Anaesthetic management of people with multiple sclerosis.

Multiple sclerosis and related disorders·2023
Same author

Organic solvents and Multiple Sclerosis: the doubled risk dilemma.

Occupational medicine (Oxford, England)·2023
Same author

The role of laboratory testing in hospitalised and critically ill COVID-19-positive patients.

The Southern African journal of critical care : the official journal of the Critical Care Society·2023
Same author

Quality of amoxicillin/clavulanic acid oral formulations for intended veterinary use in the UK, Malaysia, Serbia and Thailand.

The Journal of small animal practice·2023
Same author

South African guidelines on the determination of death.

The Southern African journal of critical care : the official journal of the Critical Care Society·2023

Video Experimental Relacionado

Updated: May 5, 2026

Tobacco Hornworm as an Insect Model System for Cannabinoid Pre-clinical Studies
05:25

Tobacco Hornworm as an Insect Model System for Cannabinoid Pre-clinical Studies

Published on: December 29, 2021

2.3K

Los cannabinoides controlan la espasticidad y el temblor en un modelo de esclerosis múltiple.

D Baker1, G Pryce, J L Croxford

  • 1Department of Neurochemistry, Institute of Neurology, University College London, UK. D.Baker@ion.ucl.ac.uk

Nature
|March 15, 2000
PubMed
Resumen

El agonismo del receptor cannabinoide redujo efectivamente la espasticidad y el temblor en un modelo de ratón con esclerosis múltiple. Esto sugiere que el sistema cannabinoide endógeno juega un papel en el control de estos síntomas debilitantes.

Más Videos Relacionados

Oromucosal as an Alternative Method for Administration of Cannabis Products in Rodents
03:43

Oromucosal as an Alternative Method for Administration of Cannabis Products in Rodents

Published on: August 22, 2025

781
Administration of &#916;9-Tetrahydrocannabinol (THC) in Adolescent and Adult Mice
07:51

Administration of Δ9-Tetrahydrocannabinol (THC) in Adolescent and Adult Mice

Published on: August 1, 2025

1.3K

Videos de Experimentos Relacionados

Last Updated: May 5, 2026

Tobacco Hornworm as an Insect Model System for Cannabinoid Pre-clinical Studies
05:25

Tobacco Hornworm as an Insect Model System for Cannabinoid Pre-clinical Studies

Published on: December 29, 2021

2.3K
Oromucosal as an Alternative Method for Administration of Cannabis Products in Rodents
03:43

Oromucosal as an Alternative Method for Administration of Cannabis Products in Rodents

Published on: August 22, 2025

781
Administration of &#916;9-Tetrahydrocannabinol (THC) in Adolescent and Adult Mice
07:51

Administration of Δ9-Tetrahydrocannabinol (THC) in Adolescent and Adult Mice

Published on: August 1, 2025

1.3K

Área de la Ciencia:

  • La neurociencia es la neurociencia.
  • Inmunología Inmunología.
  • Farmacología Farmacología.

Sus antecedentes:

  • La encefalomielitis alérgica experimental crónica recidivante (CREAE) es un modelo para la esclerosis múltiple (EM).
  • Los pacientes con EM informan beneficios del cannabis para el temblor y la espasticidad, pero la evidencia es en gran medida anecdótica.
  • El temblor y la espasticidad son síntomas desafiantes tanto en CREAE como en EM.

Objetivo del estudio:

  • Investigar el potencial terapéutico del agonismo del receptor cannabinoide para el temblor y la espasticidad en ratones CREAE.
  • Para explorar el papel del sistema cannabinoide endógeno en el control de estos síntomas.

Principales métodos:

  • Se administraron agonistas de los receptores cannabinoides (R(+) -WIN 55,212, delta9-tetrahidrocannabinol, metanandamida, JWH-133) a ratones CREAE.
  • Se utilizan antagonistas de los receptores cannabinoides (SR141716A, SR144528) para bloquear los receptores CB1 y CB2.
  • Se evaluó cuantitativamente la mejora del temblor y la espasticidad.

Principales resultados:

  • El agonismo del receptor cannabinoide redujo significativamente el temblor y la espasticidad en ratones enfermos.
  • El antagonismo de los receptores CB1 y CB2, particularmente CB1, exacerbó estos síntomas.
  • Estos hallazgos indican la actividad tónica del sistema cannabinoide endógeno en el control del temblor y la espasticidad.

Conclusiones:

  • La activación del receptor cannabinoide ofrece una estrategia terapéutica potencial para el manejo del temblor y la espasticidad en la EM.
  • El sistema cannabinoide endógeno participa activamente en la regulación de estos síntomas neurológicos.
  • Este estudio proporciona una base para evaluar los cannabinoides selectivos para el manejo de los síntomas de la EM.